Keith C Ferdinand

Summary

Affiliation: Heartbeats Life Center
Country: USA

Publications

  1. pmc A review of the efficacy and tolerability of combination amlodipine/valsartan in non-white patients with hypertension
    Keith C Ferdinand
    Division of Cardiology, Tulane University School of Medicine, and Association of Black Cardiologists, Inc, 1430 Tulane Ave, SL 48, New Orleans, LA, 70112, USA
    Am J Cardiovasc Drugs 13:301-13. 2013
  2. doi request reprint Community-based approaches to prevention and management of hypertension and cardiovascular disease
    Keith C Ferdinand
    American Society of Hypertension Community Outreach Program, Tulane Heart and Vascular Institute, Tulane University School of Medicine, 1430 Tulane Avenue, SL 48, New Orleans, LA 70112, USA
    J Clin Hypertens (Greenwich) 14:336-43. 2012
  3. doi request reprint Aliskiren-based dual- and triple-combination therapies in high-risk US minority patients with stage 2 hypertension
    Keith C Ferdinand
    Division of Cardiology, Tulane Heart and Vascular Institute, Tulane University School of Medicine, New Orleans, LA 70112, USA
    J Am Soc Hypertens 6:219-27. 2012
  4. doi request reprint One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response
    Keith C Ferdinand
    Association of Black Cardiologists and Atlanta Clinical Research Center, Tucker, GA 30084, USA
    Am J Cardiovasc Drugs 12:117-25. 2012
  5. doi request reprint Hypertension in the US Black population: risk factors, complications, and potential impact of central aortic pressure on effective treatment
    Keith C Ferdinand
    Division of Cardiology, Tulane University School of Medicine and Association of Black Cardiologists, Inc, 1430 Tulane Ave, SL 48, New Orleans, LA 70112, USA
    Cardiovasc Drugs Ther 26:157-65. 2012
  6. ncbi request reprint African American heart failure trial: role of endothelial dysfunction and heart failure in African Americans
    Keith C Ferdinand
    Division of Cardiology and the Clinical Research Center, Morehouse School of Medicine, Atlanta, Georgia 30310, USA
    Am J Cardiol 99:3D-6D. 2007
  7. ncbi request reprint Amlodipine/Atorvastatin single-pill therapy for blood pressure and lipid goals in African Americans: influence of the metabolic syndrome and type 2 diabetes mellitus
    Keith C Ferdinand
    Association of Black Cardiologists, Atlanta, GA 30349, USA
    J Clin Hypertens (Greenwich) 11:585-93. 2009
  8. doi request reprint Peripheral and central blood pressure responses of combination aliskiren/hydrochlorothiazide and amlodipine monotherapy in African American patients with stage 2 hypertension: the ATLAAST trial
    Keith C Ferdinand
    Cardiology Division, Emory University, Atlanta, GA 30349, USA
    J Clin Hypertens (Greenwich) 13:366-75. 2011
  9. ncbi request reprint Achieving treatment goals in low-risk, asymptomatic patients
    Keith C Ferdinand
    Division of Cardiology, Emory University
    J Am Osteopath Assoc 110:S7-13. 2010
  10. doi request reprint Efficacy and safety of aliskiren-based dual and triple combination therapies in US minority patients with stage 2 hypertension
    Keith C Ferdinand
    Emory University, Atlanta, GA 30349, USA
    J Am Soc Hypertens 5:102-13. 2011

Detail Information

Publications71

  1. pmc A review of the efficacy and tolerability of combination amlodipine/valsartan in non-white patients with hypertension
    Keith C Ferdinand
    Division of Cardiology, Tulane University School of Medicine, and Association of Black Cardiologists, Inc, 1430 Tulane Ave, SL 48, New Orleans, LA, 70112, USA
    Am J Cardiovasc Drugs 13:301-13. 2013
    ..These drug classes have complementary mechanisms of action and, when used concomitantly, the magnitude of blood pressure lowering in these non-white populations is generally comparable with that seen in non-Hispanic white patients...
  2. doi request reprint Community-based approaches to prevention and management of hypertension and cardiovascular disease
    Keith C Ferdinand
    American Society of Hypertension Community Outreach Program, Tulane Heart and Vascular Institute, Tulane University School of Medicine, 1430 Tulane Avenue, SL 48, New Orleans, LA 70112, USA
    J Clin Hypertens (Greenwich) 14:336-43. 2012
    ..Contemporary major federal programs, such as the Million Hearts Initiative, are ongoing. Overall, the evidence-based Logic Model should enhance planning, implementation, and dissemination...
  3. doi request reprint Aliskiren-based dual- and triple-combination therapies in high-risk US minority patients with stage 2 hypertension
    Keith C Ferdinand
    Division of Cardiology, Tulane Heart and Vascular Institute, Tulane University School of Medicine, New Orleans, LA 70112, USA
    J Am Soc Hypertens 6:219-27. 2012
    ..However, because our subgroups were not mutually exclusive, the generalization of our findings to the population seen in clinical practice is limited...
  4. doi request reprint One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response
    Keith C Ferdinand
    Association of Black Cardiologists and Atlanta Clinical Research Center, Tucker, GA 30084, USA
    Am J Cardiovasc Drugs 12:117-25. 2012
    ....
  5. doi request reprint Hypertension in the US Black population: risk factors, complications, and potential impact of central aortic pressure on effective treatment
    Keith C Ferdinand
    Division of Cardiology, Tulane University School of Medicine and Association of Black Cardiologists, Inc, 1430 Tulane Ave, SL 48, New Orleans, LA 70112, USA
    Cardiovasc Drugs Ther 26:157-65. 2012
    ..The purpose of this paper is to review these factors and discuss how they present unique opportunities for improving the management of hypertension in this difficult-to-treat population...
  6. ncbi request reprint African American heart failure trial: role of endothelial dysfunction and heart failure in African Americans
    Keith C Ferdinand
    Division of Cardiology and the Clinical Research Center, Morehouse School of Medicine, Atlanta, Georgia 30310, USA
    Am J Cardiol 99:3D-6D. 2007
    ..When added to standard therapy, isosorbide dinitrate and hydralazine provide an evidence-based approach to diminishing morbidity and mortality in this high-risk population...
  7. ncbi request reprint Amlodipine/Atorvastatin single-pill therapy for blood pressure and lipid goals in African Americans: influence of the metabolic syndrome and type 2 diabetes mellitus
    Keith C Ferdinand
    Association of Black Cardiologists, Atlanta, GA 30349, USA
    J Clin Hypertens (Greenwich) 11:585-93. 2009
    ..9 mg vs maximum of 80 mg). Reluctance to intensify therapy to attain accepted targets in high-risk individuals suggests a degree of clinical inertia not explained by objective evidence of dose-dependent intolerance...
  8. doi request reprint Peripheral and central blood pressure responses of combination aliskiren/hydrochlorothiazide and amlodipine monotherapy in African American patients with stage 2 hypertension: the ATLAAST trial
    Keith C Ferdinand
    Cardiology Division, Emory University, Atlanta, GA 30349, USA
    J Clin Hypertens (Greenwich) 13:366-75. 2011
    ..Central pressure is considered an important risk factor in African Americans, and these findings may suggest a new treatment option for these patients...
  9. ncbi request reprint Achieving treatment goals in low-risk, asymptomatic patients
    Keith C Ferdinand
    Division of Cardiology, Emory University
    J Am Osteopath Assoc 110:S7-13. 2010
    ..As the present case-based activity demonstrates, determining appropriate diagnostic and management strategies according to CHD risk is a process that challenges physicians to consider myriad individual patient variables...
  10. doi request reprint Efficacy and safety of aliskiren-based dual and triple combination therapies in US minority patients with stage 2 hypertension
    Keith C Ferdinand
    Emory University, Atlanta, GA 30349, USA
    J Am Soc Hypertens 5:102-13. 2011
    ..2% and 40.2%, respectively. Combination aliskiren/amlodipine therapy was effective in treating these high-risk patients but inclusion of HCTZ provided greater antihypertensive efficacy. Both treatments were similarly well tolerated...
  11. ncbi request reprint Management of cardiovascular risk in patients with type 2 diabetes mellitus as a component of the cardiometabolic syndrome
    Keith C Ferdinand
    Heartbeats Life Center, New Orleans, LA, USA
    J Cardiometab Syndr 1:133-40. 2006
    ....
  12. ncbi request reprint Trends in hypertension treatment in diabetes
    Keith C Ferdinand
    Association of Black Cardiologists, 5355 Hunter Road, Atlanta, GA 30349, USA
    Curr Hypertens Rep 11:437-43. 2009
    ..Clinical evidence may soon confirm or refute the outcomes benefit of blood pressure targets of 120/80 mm Hg or lower...
  13. ncbi request reprint Management of hypertension and dyslipidemia
    Keith C Ferdinand
    Association of Black Cardiologists, Inc, 5355 Hunter Road, Atlanta, GA 30349, USA
    Curr Hypertens Rep 8:489-96. 2006
    ..Patient adherence may affect achievement of recommended goals of therapy for dyslipidemia and hypertension. Effective education and communication may improve overall achievement of treatment goals...
  14. ncbi request reprint Ethnic, gender, and age-related differences in the treatment of dyslipidemia
    Keith C Ferdinand
    Emory University Chief Scientific Officer of Association of Black Cardiologists, 5355 Hunter Rd, Atlanta, GA 30349, USA
    Am J Manag Care 12:S400-4. 2006
    ..This article will explore the evidence for instituting statin therapy as part of a risk reducing strategy in older individuals, women, and ethnic minorities...
  15. doi request reprint Are cardiovascular benefits in statin lipid effects dependent on baseline lipid levels?
    Keith C Ferdinand
    Division of Cardiology, Emory University, 5355 Hunter Rd, Atlanta, GA 30349, USA
    Curr Atheroscler Rep 13:64-72. 2011
    ..Preconceived notions on statin benefit or harm do not enhance patient care and clinicians should individualize long-term statin therapy...
  16. ncbi request reprint The management of hypertension with angiotensin receptor blockers in special populations
    Keith C Ferdinand
    Division of Cardiology Emory University School of Medicine, Atlanta, Georgia 30349, USA
    Clin Cornerstone 9:S5-17. 2009
    ..Although at least 1 major study has confirmed the benefit of ARBs in Asian patients with diabetic nephropathy, overall, treating patients based on race and ethnicity remains fraught with difficulty...
  17. doi request reprint Race-based therapy for hypertension: possible benefits and potential pitfalls
    Keith C Ferdinand
    Division of Cardiology, Emory University, Atlanta, GA, USA
    Expert Rev Cardiovasc Ther 6:1357-66. 2008
    ..Current guidelines recommend thiazide diuretics and/or long-acting calcium channel blockers as initial treatment for Blacks, although medications for compelling indications agents should be prescribed, regardless of race/ethnicity...
  18. ncbi request reprint Coronary artery disease in minority racial and ethnic groups in the United States
    Keith C Ferdinand
    Heartbeats Life Center and Department of Clinical Pharmacology, Xavier University College of Pharmacy, New Orleans, Louisiana, USA
    Am J Cardiol 97:12A-19A. 2006
    ..There remain significant challenges to understanding racial/ethnic differences in cardiovascular risk factors and to including minority groups in clinical trials of therapeutic interventions, thereby ensuring optimal treatment for all...
  19. doi request reprint Vascular effects of nebivolol added to hydrochlorothiazide in African Americans with hypertension and echocardiographic evidence of diastolic dysfunction: the NASAA study
    Bobby V Khan
    Atlanta Vascular Research Foundation, Atlanta, GA 30084, USA
    J Cardiovasc Pharmacol Ther 17:291-7. 2012
    ..We investigated the effects of nebivolol with the diuretic hydrochlorothiazide (HCTZ) in hypertensive African Americans with echocardiographic evidence of diastolic dysfunction...
  20. ncbi request reprint The management of hypertension in African Americans
    Keith C Ferdinand
    Association of Black Cardiologists, Critical Pathways in Cardiology, Boston, MA 02115, USA
    Crit Pathw Cardiol 6:67-71. 2007
    ..Of note, African American patients with systolic BP >15 mm Hg or a diastolic BP >10 mm Hg above goal should be treated with first-line combination therapy...
  21. ncbi request reprint Changes in biomarkers and 24 hours blood pressure in hypertensive African Americans with the metabolic syndrome: comparison of amlodipine/olmesartan versus hydrochlorothiazide/losartan
    Nadya Merchant
    Atlanta Vascular Research Foundation, Atlanta, GA
    J Am Soc Hypertens 7:386-94. 2013
    ....
  22. ncbi request reprint Hypertension-related morbidity and mortality in African Americans--why we need to do better
    Keith C Ferdinand
    Heartbeats Life Center, Xavier University College of Pharmacy, New Orleans, LA, USA
    J Clin Hypertens (Greenwich) 8:21-30. 2006
    ..These comorbidities are more common in African Americans and indicate the potential need for initial therapy with more than one agent or a combination of agents in one pill...
  23. pmc Irbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy
    Elizabeth O Ofili
    Clinical Research Center, Morehouse School of Medicine, Atlanta, GA 30310, USA
    J Natl Med Assoc 98:618-26. 2006
    ..In conclusion, irbesartan/HCTZ treatment provided SBP/DBP goal attainment in approximately two-thirds of Caucasian, African-American and Hispanic/Latino patients with SBP uncontrolled on antihypertensive monotherapy...
  24. ncbi request reprint Recommendations for the management of special populations: racial and ethnic populations
    Keith C Ferdinand
    Heartbeats Life Center, Xavier University College of Pharmacy, New Orleans, Louisiana 70117, USA
    Am J Hypertens 16:50S-54S. 2003
    ..Although certain combinations have been shown to be effective in non-African American patients, the choice of drugs for combination therapy in African American patients may be different...
  25. pmc Managing cardiovascular risk in minority patients
    Keith C Ferdinand
    Heartbeats Life Center, New Orleans, LA 70117, USA
    J Natl Med Assoc 97:459-66. 2005
    ..Large, ongoing epidemiologic and clinical trials will add to our knowledge of cardiovascular risk in these minority populations and contribute to recommendations to improve risk management...
  26. ncbi request reprint Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six-week trial
    Keith C Ferdinand
    Heartbeats Life Center, Xavier University College of Pharmacy, New Orleans, Louisiana, USA
    Am J Cardiol 97:229-35. 2006
    ..In conclusion, rosuvastatin 10 and 20 mg improved the overall lipid profile of hypercholesterolemic African-Americans better than did milligram-equivalent doses of atorvastatin...
  27. ncbi request reprint Contemporary treatment of heart failure: is there adequate evidence to support a unique strategy for African-Americans? Con position
    Keith C Ferdinand
    Heartbeats Life Center, Xavier University of Louisiana, College of Pharmacy, 1201 Poland Avenue, New Orleans, LA 70117, USA
    Curr Hypertens Rep 4:311-8. 2002
    ..The use of evidence-based therapies should be equally applied to African-Americans as well as to other ethnic groups while awaiting further studies...
  28. pmc Nebivolol in high-risk, obese African Americans with stage 1 hypertension: effects on blood pressure, vascular compliance, and endothelial function
    Nadya Merchant
    Department of Cardiology, Emory University, 69 Jesse Hill Drive SE, Atlanta, GA30303, USA
    J Clin Hypertens (Greenwich) 11:720-5. 2009
    ..005). Monotherapy with nebivolol in obese, hypertensive African Americans results in significant systolic and diastolic BP reduction by mechanisms that include improved vascular function and compliance...
  29. ncbi request reprint The metabolic syndrome: recognition and management
    W Dallas Hall
    Emory University School of Medicine, Atlanta, GA, USA
    Dis Manag 9:16-33. 2006
    ..Pharmacotherapy is typically needed for control of high blood pressure, hypercoagulability, and increased levels of blood glucose and triglycerides...
  30. ncbi request reprint Prehypertension and the cardiometabolic syndrome: is there any value in pharmacologic intervention?
    Keith C Ferdinand
    Heartbeats Life Center, New Orleans, LA, USA
    J Cardiometab Syndr 1:146-8. 2006
    ....
  31. ncbi request reprint Rosuvastatin: a risk-benefit assessment for intensive lipid lowering
    Keith C Ferdinand
    College of Pharmacy, Xavier University, New Orleans, LA 70117, USA
    Expert Opin Pharmacother 6:1897-910. 2005
    ..Therefore, rosuvastatin offers an effective alternative in the clinical management of hyperlipidaemia, while awaiting the results of ongoing cardiovascular risk reduction trials...
  32. doi request reprint Obesity and hypertension: It's about more than the numbers
    Keith C Ferdinand
    Tulane Heart and Vascular Institute, Tulane University School of Medicine, New Orleans, LA 70112, USA
    Obesity (Silver Spring) 21:657-8. 2013
    ..This editorial comments on the recent Obesity Society and American Society of Hypertension joint position paper, justified by the substantial link between obesity and hypertension (HTN)...
  33. doi request reprint The impact of lipoic acid on endothelial function and proteinuria in quinapril-treated diabetic patients with stage I hypertension: results from the QUALITY study
    Syed T Rahman
    Emory University School of Medicine, Division of Cardiology, Atlanta, GA, USA
    J Cardiovasc Pharmacol Ther 17:139-45. 2012
    ....
  34. doi request reprint Fixed-dose isosorbide dinitrate-hydralazine: race-based cardiovascular medicine benefit or mirage?
    Keith C Ferdinand
    Cardiology Division, Emory University, USA
    J Law Med Ethics 36:458-63. 2008
    ..Future research may unmask the reason for cardiovascular differences in therapy...
  35. ncbi request reprint Coronary heart disease and lipid-modifying treatment in African American patients
    Keith C Ferdinand
    Heartbeats Life Center, New Orleans, LA 70117, USA
    Am Heart J 147:774-82. 2004
    ..Educational outreach programs can provide a key role in raising community awareness of CHD risk factors and potential treatment options...
  36. pmc Public health and Hurricane Katrina: lessons learned and what we can do now
    Keith C Ferdinand
    Association of Black Cardiologists Hurricane Katrinia Relief, Atlanta, GA, USA
    J Natl Med Assoc 98:271-4. 2006
    ..The hurricane destroyed hiss cardiovascular center and severely damaged his home. In Atlanta, he is director of the Association of Black Cardiologists Hurricane Katrina Relief...
  37. ncbi request reprint The cardiometabolic syndrome and cardiovascular disease in racial and ethnic minorities: new areas of research and intervention
    Keith C Ferdinand
    Association of Black Cardiologists, Atlanta, GA
    J Cardiometab Syndr 2:235-7. 2007
  38. ncbi request reprint Cardiovascular disease in blacks: can we stop the clock?
    Keith C Ferdinand
    Emory University and the Association of Black Cardiologists, Atlanta, GA 30349, USA
    J Clin Hypertens (Greenwich) 10:382-9. 2008
    ..However, renin-angiotensin system modulators may also be beneficial, especially with a diuretic, considering the high prevalence in this group of patients of compelling indications for use of such agents...
  39. ncbi request reprint Hypertension in minority populations
    Keith C Ferdinand
    Association of Black Cardiologists, Inc, Atlanta, GA 30349, USA
    J Clin Hypertens (Greenwich) 8:365-8. 2006
    ..7% to 0.8%. Asians and Pacific Islanders as a category will become a larger proportion, from 3.9% to 6.2%. The largest increase in proportion will be seen in those identified as Hispanic (of any race), from 11.8% in 2002 to 18.2% in 2025...
  40. ncbi request reprint Primary prevention trials: lessons learned about treating high-risk patients with dyslipidemia without known cardiovascular disease
    Keith C Ferdinand
    Heartbeats Life Center, New Orleans, LA 70117, USA
    Curr Med Res Opin 21:1091-7. 2005
    ..This subset of at-risk patients is better served by this approach than by treatment solely based on degree of dyslipidemia...
  41. ncbi request reprint Hypertension and the cardiometabolic syndrome--is it the blood pressure lowering or the blood pressure medication that is important?
    Keith C Ferdinand
    From the Heartbeats Life Center, Xavier University College of Pharmacy, New Orleans, LA, USA
    J Cardiometab Syndr 1:72-3. 2006
    ..This case illustrates some of the factors clinicians have utilized in approaching patients with this common but challenging clinical situation...
  42. ncbi request reprint Isosorbide dinitrate and hydralazine hydrochloride: a review of efficacy and safety
    Keith C Ferdinand
    Xavier University, College of Clinical Pharmacology, New Orleans, LA, USA
    Expert Rev Cardiovasc Ther 3:993-1001. 2005
    ..Further clinical trials utilizing isosorbide dinitrate will hopefully determine the benefit of this combination in a larger population, including caucasians and other racial/ethnic groups...
  43. doi request reprint From protocol to practice: translating the clinical data into clinical practice
    Keith C Ferdinand
    Heartbeats Life Center, 1201 Poland Ave, New Orleans, LA 70117, USA
    Postgrad Med 112:18-22. 2002
    ..Clearly, future studies must include more representative samples from these populations. Meanwhile, the Adult Treatment Panel III guidelines should be applied across the board...
  44. ncbi request reprint The importance of aggressive lipid management in patients at risk: evidence from recent clinical trials
    Keith C Ferdinand
    Heartbeats Life Center and Xavier University College of Pharmacy, New Orleans, Louisiana 70017, USA
    Clin Cardiol 27:III12-5. 2004
    ..Taken together, the results of these landmark trials not only support aggressive lipid lowering in patients at risk for CHD, but also suggest that greater LDL-C reductions may improve outcomes across a wide range of patients...
  45. ncbi request reprint New evidence confirms risks associated with prehypertension and benefits of therapeutic lifestyle changes in management
    Keith C Ferdinand
    Association of Black Cardiologists, Atlanta, GA 30349, USA
    J Cardiometab Syndr 2:302-4. 2007
    ..Based on her BP and concurrent cardiometabolic syndrome, what do you tell her about the risks associated with her BP, and how do you approach her management?..
  46. ncbi request reprint Introduction: management of hypertension and cardiovascular risk factors in African Americans
    Keith C Ferdinand
    Heartbeats Life Center, New Orleans, LA 70117, USA
    J Clin Hypertens (Greenwich) 5:3-4. 2003
  47. ncbi request reprint The epidemic of diabetes mellitus and the metabolic syndrome in African Americans
    Keith C Ferdinand
    Xavier University College of Pharmacy, Heartbeats Life Center, New Orleans, Louisiana, USA
    Rev Cardiovasc Med 5:S28-33. 2004
    ..Appropriate lifestyle modification programs, glucose control, and cardiovascular risk reduction therapy will reduce the excessive morbidity and mortality in this population...
  48. ncbi request reprint Cardiovascular health in patients with serious mental illnesses: we need to do more
    Keith C Ferdinand
    Association of Black Cardiologists, Atlanta, GA, USA
    J Clin Hypertens (Greenwich) 9:714-5. 2007
  49. ncbi request reprint The Hurricane Katrina disaster: focus on the hypertensive patient
    Keith C Ferdinand
    Heartbeats Life Center, New Orleans, LA, USA
    J Clin Hypertens (Greenwich) 7:679-80. 2005
  50. ncbi request reprint Barriers to blood pressure control in African Americans. Overcoming obstacles is challenging, but target goals can be attained
    Janice G Douglas
    Division of Hypertension, Department of Medicine, Case Western Reserve University School of Medicine, University Hospitals of Cleveland, Room W165, 10900 Euclid Ave, Cleveland, OH 44106 4982, USA
    Postgrad Med 112:51-2, 55, 59-62 passim. 2002
    ..When extensive efforts to achieve blood pressure control prove unattainable in the primary care setting, consultation with a hypertension specialist should be considered...
  51. ncbi request reprint Optimal treatment of hypertension in African Americans. Reaching and maintaining target blood pressure goals
    George L Bakris
    Departments of Preventive Medicine and Internal Medicine, Rush Hypertension Clinical Research Center, Rush Presbyterian St Luke s Medical Center, 1700 W Van Buren St, Suite 470, Chicago, IL 60612, USA
    Postgrad Med 112:73-4, 77-80, 83-4. 2002
    ..This article describes current "best practice" guidance on appropriate treatment of high blood pressure in African Americans. Two patient scenarios offer insight into clinical strategies...
  52. ncbi request reprint Hypertension-related disease in African Americans. Factors underlying disparities in illness and its outcome
    James R Sowers
    Departments of Medicine, Biochemistry, and Cell Biology, State University of New York Health Science Center, Brooklyn College of Medicine, Brooklyn, NY 11203, USA
    Postgrad Med 112:24-6, 29-30, 33-4 passim. 2002
    ..In this article, Drs Sowers, Ferdinand, Bakris, and Douglas examine the biologic, social, and genetic factors that contribute to these health disparities, the risk for which appears in early childhood...
  53. ncbi request reprint Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks
    Janice G Douglas
    Case Western Reserve University, Department of Medicine, Room W 165, 10900 Euclid Ave, Cleveland, Ohio 44106, USA
    Arch Intern Med 163:525-41. 2003
  54. ncbi request reprint Retrospective analysis: consensus statement of the hypertension in African Americans working group of the International Society on Hypertension in Blacks (ISHIB)
    Keith C Ferdinand
    Ethn Dis 15:3-5. 2005
  55. ncbi request reprint A noninferiority comparison of valsartan/hydrochlorothiazide combination versus amlodipine in black hypertensives
    Matthew R Weir
    Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Hypertension 46:508-13. 2005
    ..5 mg) is as effective as high-dose amlodipine (10 mg) in reducing blood pressure in blacks with stage 1 and stage 2 hypertension, and valsartan/hydrochlorothiazide is better tolerated...
  56. ncbi request reprint The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial
    Joel M Neutel
    Orange County Research Center, Tustin, CA 92780, USA
    J Clin Hypertens (Greenwich) 7:578-86. 2005
    ..Treatments were well tolerated. This irbesartan/HCTZ treatment regimen achieved SBP goals in more than 75% of patients uncontrolled on monotherapy...
  57. ncbi request reprint The isosorbide-hydralazine story: is there a case for race-based cardiovascular medicine?
    Keith C Ferdinand
    J Clin Hypertens (Greenwich) 8:156-8. 2006
  58. ncbi request reprint Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes
    James R Sowers
    University of Missouri Columbia and Harry S Truman VA Medical Center, 65212, USA
    J Clin Hypertens (Greenwich) 8:470-80. 2006
    ..Irbesartan/HCTZ fixed combinations achieved SBP goals in over half of the T2DM patients and nearly three quarters of patients with the metabolic syndrome, with SBP uncontrolled on antihypertensive monotherapy...
  59. ncbi request reprint New antihypertensive agents: will they work in blacks?
    Keith C Ferdinand
    J Clin Hypertens (Greenwich) 9:165-7. 2007
  60. ncbi request reprint Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapy
    William C Cushman
    University of Tennessee College of Medicine and Veterans Affairs Medical Center, Memphis, TN, USA
    Am J Geriatr Cardiol 17:27-36. 2008
    ..Irbesartan/HCTZ combination therapy allowed SBP goal attainment in 73% of patients aged 65 years or older whose hypertension was previously uncontrolled with antihypertensive monotherapy...
  61. doi request reprint Improved attainment of blood pressure and cholesterol goals using single-pill amlodipine/atorvastatin in African Americans: the CAPABLE trial
    John M Flack
    Department of Medicine, Wayne State University, Detroit, MI 48201, USA
    Mayo Clin Proc 83:35-45. 2008
    ..To investigate the efficacy and safety of single-pill amlodipine/atorvastatin therapy for the simultaneous treatment of hypertension (HTN) and dyslipidemia in African Americans...
  62. ncbi request reprint Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial
    Jalal K Ghali
    University Health Center, Wayne State University, Detroit, MI 48201, USA
    Am J Cardiovasc Drugs 7:373-80. 2007
    ....
  63. pmc Cardiovascular disease and African Americans: why determination of race is inadequate for research and practice
    Keith C Ferdinand
    J Natl Med Assoc 99:686-9. 2007
  64. ncbi request reprint The management of hypertension in the African American patient
    Jackson T Wright
    Medicine, Case Western Reserve University, Cleveland, OH, USA
    J Clin Hypertens (Greenwich) 9:468-75. 2007
    ..The authors maintained full control of the discussion and the resulting content of this article; Novartis had no input in the choice of topic, speakers, or content...
  65. ncbi request reprint Barbershops as hypertension detection, referral, and follow-up centers for black men
    Paul L Hess
    Division of Hypertension, Donald W Reynolds Cardiovascular Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, TX 75390 8586, USA
    Hypertension 49:1040-6. 2007
    ..01). Taken together, these data suggest that black-owned barbershops can be transformed into effective HTN detection, referral, and follow-up centers. Further research is warranted...
  66. ncbi request reprint The Metabolic Syndrome in African Americans: a review
    W Dallas Hall
    African American Lipid and Cardiovascular Council, USA
    Ethn Dis 13:414-28. 2003
    ..This comprehensive review is provided as part of the educational activities of the African-American Lipid and Cardiovascular Council (AALCC)...
  67. ncbi request reprint Roundtable discussion: hypertension, renal disease, and diabetes
    Marvin Moser
    J Clin Hypertens (Greenwich) 4:113-9. 2002
    ..Following a symposium on Hypertension in Atlanta, Georgia on April 25, 2001, which was sponsored by the National Heart, Lung, and Blood Institute, a panel was convened to discuss the problems of renal disease and hypertension...
  68. ncbi request reprint Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial
    Peter H Jones
    Section of Atherosclerosis and Lipid Research, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Ther 26:1388-99. 2004
    ....
  69. ncbi request reprint For the patient. What is the Metabolic Syndrome and why is it important?
    W Dallas Hall
    Ethn Dis 13:546. 2003
  70. ncbi request reprint Blood pressure control in the patient with difficult-to-control hypertension: which agent for which patient?
    George L Bakris
    University of Chicago, IL, USA
    Prev Cardiol 11:42-9. 2008
    ..The authors maintained full control of the discussion and the resulting content of this article...
  71. ncbi request reprint Noninvasive diagnosis of subclinical atherosclerosis in cardiometabolic syndrome: a call to action
    Carol Kotliar
    Cardiology Department, Hospital Universitario Austral, Buenos Aires, Argentina
    J Cardiometab Syndr 3:60-2. 2008